samedan logo
home > pmps > spring 2021 > alternative propellants: a roadmap of green pmdi development and manufacture
Pharmaceutical Manufacturing and Packing Sourcer

Alternative Propellants: A Roadmap of Green pMDI Development and Manufacture

The urgent threat of climate change is the age-defining issue of our generation, and we are reaching a pivotal moment for our industry. The inhalation industry is committed to reducing their carbon footprint and establishing processes that are more sustainable. A global commitment to establishing a greener future must happen now; the industry’s proactive approach will address the major environmental concerns of pMDI manufacture – the carbon footprint of the propellant.

The adverse effects of greenhouse gases on our climate are well documented. This is not a new revelation, rather, this industry has gone through a similar issue before. The issue being adapting the way we formulate MDIs to develop more sustainable products, while maintaining safety and functionality.

HFO-1234ze and HFA-152a have been highlighted as potential replacements of HFA-134a and HFA-227ea. It is critical that formulation studies are performed to understand the propellant performance with inhalation APIs, particularly reliver medications.

Learn more about the proposed propellants and drivers for change from our editorial: www.pharmaservenorthwest.

As a producer of life-saving medication, Pharmaserve North West (PSNW) has committed to future-proofing our facilities, products, and processes. The issues and challenges posed by the investment into two prospective greener propellants have been addressed as a matter of urgency.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Pharmaserve North West

9 Arkwright Rd, Astmoor Industrial Estate, Runcorn, WA7 1NU, UK

T: 01928 502 200

Print this page
Send to a friend
Privacy statement
News and Press Releases

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases

MyMD Pharmaceuticals Inc., a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,085,047 titled “Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.”
More info >>

White Papers

Blockbuster Drugs Need Blockbuster Components

West Pharmaceutical Services, Inc.

Many of the world’s blockbuster drugs are now delivered via a prefilled syringe system or auto-injector. To ensure patient safety, pharmaceutical manufacturers need high-quality components that feature reduced particulates and ensure consistency of delivery while fitting the changing needs of higher-volume delivery systems.
More info >>




©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement